Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib long-term follow-up in pediatric NF1
NCT07024394Phase 2Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Jun 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by Fosun Pharma. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
luvometinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT07024394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024394.